Targeting RORgamma, Phenex, J&J Ink $135M Collaboration

Phenex Pharmaceuticals AG and Johnson & Johnson subsidiary Janssen Biotech Inc., have thrown in their lot together in a combined effort to develop antagonists of retinoic acid-related orphan receptor gamma (RORγt) for inflammatory disease.